These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30801908)

  • 1. Therapeutic efficacy evaluation of radioimmunotherapy with
    Sudo H; Tsuji AB; Sugyo A; Saga T; Kaneko MK; Kato Y; Higashi T
    Cancer Sci; 2019 May; 110(5):1653-1664. PubMed ID: 30801908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma.
    Sudo H; Tsuji AB; Sugyo A; Kaneko MK; Kato Y; Nagatsu K; Suzuki H; Higashi T
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
    Abe S; Morita Y; Kaneko MK; Hanibuchi M; Tsujimoto Y; Goto H; Kakiuchi S; Aono Y; Huang J; Sato S; Kishuku M; Taniguchi Y; Azuma M; Kawazoe K; Sekido Y; Yano S; Akiyama S; Sone S; Minakuchi K; Kato Y; Nishioka Y
    J Immunol; 2013 Jun; 190(12):6239-49. PubMed ID: 23690472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
    Kato Y; Vaidyanathan G; Kaneko MK; Mishima K; Srivastava N; Chandramohan V; Pegram C; Keir ST; Kuan CT; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2010 Oct; 37(7):785-94. PubMed ID: 20870153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 90Y-Labeled Anti-ROBO1 Monoclonal Antibody Exhibits Antitumor Activity against Small Cell Lung Cancer Xenografts.
    Fujiwara K; Koyama K; Suga K; Ikemura M; Saito Y; Hino A; Iwanari H; Kusano-Arai O; Mitsui K; Kasahara H; Fukayama M; Kodama T; Hamakubo T; Momose T
    PLoS One; 2015; 10(5):e0125468. PubMed ID: 26017283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Characterization of the Radioimmunoconjugate
    Funase Y; Nakamura E; Kajita M; Saito Y; Oshikiri S; Kitano M; Tokura M; Hino A; Uehara T
    J Nucl Med; 2021 Feb; 62(2):232-239. PubMed ID: 32737245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
    Nayak TK; Garmestani K; Milenic DE; Baidoo KE; Brechbiel MW
    PLoS One; 2011 Mar; 6(3):e18198. PubMed ID: 21464917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.
    Yoshida C; Tsuji AB; Sudo H; Sugyo A; Kikuchi T; Koizumi M; Arano Y; Saga T
    PLoS One; 2013; 8(3):e59248. PubMed ID: 23516616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
    Sugyo A; Tsuji AB; Sudo H; Koizumi M; Ukai Y; Kurosawa G; Kurosawa Y; Saga T; Higashi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
    Hanaoka H; Kuroki M; Yamaguchi A; Achmad A; Iida Y; Higuchi T; Oriuchi N; Tsushima Y; Endo K
    Cancer Biother Radiopharm; 2014 Mar; 29(2):70-6. PubMed ID: 24299067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
    Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
    Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
    Kaneko MK; Kunita A; Abe S; Tsujimoto Y; Fukayama M; Goto K; Sawa Y; Nishioka Y; Kato Y
    Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
    Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
    Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.
    Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T
    Oncotarget; 2016 Jun; 7(25):38835-38844. PubMed ID: 27246980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
    Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
    Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
    Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
    Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.